Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/perspective-hepatocyte-directed-base-editing-as-novel-treatment-for-nPUHlCcUw0
References (16)
-
C Brokowski, M Adli (2019)
CRISPR ethics: moral considerations for applications of a powerful tool., 431
-
EA Biessen, K Sliedregt-Bol, PA ‘T Hoen, P Prince, E Van der Bilt, AR Valentijn, NJ Meeuwenoord, H Princen, MK Bijsterbosch, GA Van der Marel (2002)
Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes., 13
-
I Minicocci, A Montali, MR Robciuc, F Quagliarini, V Censi, G Labbadia, C Gabiati, G Pigna, ML Sepe, F Pannozzo (2012)
Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization., 97
-
PC Rensen, LA Sliedregt, M Ferns, E Kieviet, SM van Rossenberg, SH van Leeuwen, TJ van Berkel, EA Biessen (2001)
Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo., 276
-
K Fitzgerald, M Frank-Kamenetsky, S Shulga-Morskaya, A Liebow, BR Bettencourt, JE Sutherland, RM Hutabarat, VA Clausen, V Karsten, J Cehelsky (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial., 383
-
EAL Biessen, TJC van Berkel, JH van Boom
Triantennary cluster glycosides, their preparation and use. -
A Akinc, W Querbes, S De, J Qin, M Frank-Kamenetsky, KN Jayaprakash, M Jayaraman, KG Rajeev, WL Cantley, JR Dorkin (2010)
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms., 18
-
M Farnier, D Gaudet, V Valcheva, P Minini, K Miller, B Cariou (2016)
Efficacy of alir ocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials., 223
-
KK Ray, HN Ginsberg, MH Davidson, R Pordy, L Bessac, P Minini, RH Eckel, CP Cannon (2016)
Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control., 134
-
RG Lee, AM Mazzola, MC Braun, C Platt, SB Vafai, S Kathiresan, E Rohde, AM Bellinger, AV Khera (2023)
Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models., 147
-
KK Ray, E Bruckert, P Peronne-Filardi, C Ebenbichler, A Vogt, I Bridges, M Sibartie, N Dhalwani (2023)
Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study., 366
-
F Arabi, V Mansouri, N Ahmadbeigi (2022)
Gene therapy clinical trials, where do we go? An overview., 153
-
EA Biessen, H Vietsch, ET Rump, K Fluiter, J Kuiper, MK Bijsterbosch, TJ van Berkel (1999)
Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo., 340
-
JC Cohen, E Boerwinkle, TH Mosley, HH Hobbs (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease., 354
-
KK Ray, FJ Raal, DG Kallend, MJ Jaros, W Koenig, LA Leiter, U Landmesser, GG Schwartz, D Lawrence, A Friedman (2023)
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials., 44
-
H Moradian, T Roch, A Lendlein, M Gossen (2020)
mRNA transfection-induced activation of primary human monocytes and macrophages: dependence on carrier system and nucleotide modification., 10
- Publisher
- Wolters Kluwer Health
- Copyright
- © 2023 American Heart Association, Inc.
- ISSN
- 1079-5642
- eISSN
- 1524-4636
- DOI
- 10.1161/atvbaha.122.318354
- Publisher site
- See Article on Publisher Site
Abstract
Hyperlipidemia is a major risk factor for the development of atherosclerotic cardiovascular disease. Lipid-lowering drug therapies therefore still form the heart of the ongoing battle against the occurrence of cardiovascular events. However, in light of the important improvements in gene interference and editing that have been made during the last 2 decades, gene therapy—the genetic modification of cells to produce a permanent therapeutic effect—is currently employed to relief hypercholesterolemic subjects from their potential (chronic) cardiovascular disease burden. In this perspective, we review the current status regarding hepatocyte-directed base editing to treat human dyslipidemia and provide suggestions for further technological improvement.
Journal
Arteriosclerosis Thrombosis and Vascular Biology – Wolters Kluwer Health
Published: Jun 27, 2023